Scientific Session 5
CMI-P-17
Minoru Yoshida
RIKEN
Executive Vice President
Japan
Chemical genomics, Drug discovery, Target identification
B.S., 1981, University of Tokyo, Ph.D., 1986, University of Tokyo; Assistant Professor., 1986-1994, University of Tokyo, Associate Professor, 1994-2002, University of Tokyo, Chief Scientist, 2002-2017, RIKEN, Group Director, 2008-2023, RIKEN, Professor, 2017-2023, University of Tokyo, Executive Vice President, 2023-present, RIKEN, University Professor, 2023-present, University of Tokyo
Target ID of pentadecanoic acid. Hoshikawa, Y. et al. PNAS 122, e2422126122 (2025)
Target ID of Girolline. Schneider-Poetsch T, et al. Nat. Commun. 16, 223 (2025)
Drug discovery for Sickle Cell Disease. Takase, S. et al. Nat. Commun. 14, 23 (2023)
Long-chain fatty acylation of TEAD. Noritsugu, K. et al. Cell Rep. 12, 112388 (2023)
Development of histone metylation sensors. Sasaki, K. et al. Cell Chem. Biol. 29, 1153-1161.e5. (2022)
Translation suppression by intron-derived proteins. Chhipi-Shrestha, J.K. et al. Cell Chem. Biol. 29, 259-275 (2022)
Mechanism of action of spliceostatin A. Yoshimoto, R. et al. Cell Chem. Biol. 28, 1356-1365.e4. (2021)
Drug discovery for mitochondrial disease. Kobayashi, H. et al. Nat. Chem. Biol. 17, 335-343 (2021)
High throughput screening facilities, Drug discovery capability, and target ID by chemical genomics
